Adela
Signal active
Organization
Contact Information
Overview
Adela develops innovative and accessible technologies focusing on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. Adela’s genome-wide methylome enrichment platform captures information efficiently from the entire methylome. Its technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
About
Industries
Biotechnology, Health Care, Medical, Health Diagnostics
Founded
2020
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Adela headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $3.5B in funding across 32 round(s). With a team of 51-100 employees, Adela is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Adela, raised $48.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
6
Lead Investors
0
Total Funding Amount
$108.0M
Details
2
Adela has raised a total of $108.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 60.0M | ||
| 2023 | Early Stage Venture | 48.0M |
Investors
Adela is funded by 15 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| OrbiMed | - | FUNDING ROUND - OrbiMed | 48.0M |
| LabCorp | - | FUNDING ROUND - LabCorp | 48.0M |
| Adela | - | FUNDING ROUND - Adela | 48.0M |
| F-Prime Capital | - | FUNDING ROUND - F-Prime Capital | 48.0M |
Recent Activity
There is no recent news or activity for this profile.